Targets for OA pain pharmacotherapies some by the wayside: - NGF - TrkA but some very much in play and exciting: - neurotrophin-3 - TRPV1 - Nav1.7, 1.8 Fiona Watt #EULAR2025 @RheumNow https://t.co/DXDKNnVRRo

In the APEX Phase 3b RCT (N=1020), guselkumab (IL-23p19 inhibitor) significantly reduced radiographic progression (ΔvdH-S 0.55 & 0.54 vs 1.35 PBO; p≤0.002) and improved ACR20 (67–68% vs 47%) at W24 in biologic-naïve PsA. Safety consistent with prior data. Abstract LB0010 https://t.co/mFDsBsCg6m

Migrant health literacy challenges - Individual interviews with participants with rheumatic diseases (interpreters used) multiple aspects - Individual, Providers and system level Navigating health care systems #EULAR2025 @RheumNow https://t.co/cWQ6jP8RZe

RCT in axSpA (N=200): Digital therapeutic Axia added to stable treatment led to significant improvements in BASDAI (–1.66), BASFI (–1.12), ASQoL (–2.51), with ASAS20/40 responses of 51%/23% vs 9%/3% for usual care. Supports role of DTx in axSpA care. Abstract LB0002 @RheumNow https://t.co/oF6bjIwNIY

LEVI-04 (neutrophin-3 inhibitor presented as #ACR24 late-breaker in knee OA) more good efficacy data, no rapidly progressive OA safety signal. For us clinicians: impressive impact size, esp relative to alternatives. Finally, something that works?? #EULAR2025 OP0374 @RheumNow https://t.co/iVdlwyaqrv

It’s a hot topic at #EULAR2025, but the messages on AI in medicine from patient-professional discussions is clear: - potential upside massive in many domains, but - patients still want their clinicians by their side #EULAR2025 meeting highlights @RheumNow https://t.co/4T6gE7TeQp

Great talk by @Lupusreference on Relapsing Polychondritis and a highlight of #EULAR2025. Do not forget about the articular presentations of relapsing polychondritis @RheumNow https://t.co/1xZY7VkX1z

EULAR Classification criteria for hemachromatosis, presented by Prof. Kiely shows clinical pearls in diagnosis - Hook osteophytes @MCP 2/3, & Iron Fist sign w/ elevation of MCPs 2&3. #EULAR2025 https://t.co/S8iA0C4pwG

EULAR 2025 - Day 1 Report Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1. https://t.co/ycQT2dfVXe https://t.co/Qa58ofW411

Health Literacy Matters in Rheumatic Disease Care Dr. Mrinalini Dey reports on abstract OP0026, "Health literacy associates with clinical, treatment and work status in people with inflammatory arthritis: Results from a national cohort", presented at EULAR 2025 in Barcelona, https://t.co/f45rxHBYnY

NMA of 14RCTs (>2500 pts) eval relative efficacy of bDMARDs and tsDMARDs in mostly biologic naïve nr-axSpA pts. -All therapies studied significantly improved ASAS40 response rates compared to placebo. -Certolizumab and Golimumab were the most effective therapies, followed by https://t.co/BJLRpEDYrv

👁️Uveitis in axSpA: -Up to 40% can present before SpA dx -NMA of 44 RCTs showed tx with TNFi, JAKi and IL-17i protective effects against uveitis -Low rates of uveitis in axSpA pts on BIME trials suggests its possible beneficial effects. #EULAR2025 @RheumNow https://t.co/mPuSMnD1Zs